Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Comparative Effectiveness of COPD Treatments

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: LABA and the LAMA tiotropium (LABA-TIO)
Drug: LABA and an ICS (LABA-ICS)

First Posted Date: 2017-12-18

Last Posted Date: 2019-07-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 3954

Registration Number: NCT03376295

Locations: 🇨🇦
Centre for Clinical Epidemiology, McGill University, Montreal, Canada

Afatinib Osimertinib Sequencing NIS

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Afatinib
Drug: Osimertinib

First Posted Date: 2017-12-12

Last Posted Date: 2020-12-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 204

Registration Number: NCT03370770

Locations: 🇦🇹
Otto-Wagner Hospital, Vienna, Austria

Comparative Effectiveness of Empagliflozin in the US

Active, not recruiting

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Empagliflozin
Drug: DPP-4 inhibitor
Drug: GLP-1 receptor agonist

First Posted Date: 2017-12-06

Last Posted Date: 2025-01-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 230000

Registration Number: NCT03363464

Locations: 🇺🇸
Bringham Women Hospital, Boston, Massachusetts, United States

PraxbindTM India PMS Program

Completed

Conditions: Thromboembolism

Interventions: Drug: PraxbindTM

First Posted Date: 2017-12-02

Last Posted Date: 2023-08-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 5

Registration Number: NCT03359889

Locations: 🇮🇳
Mazumdar Shaw Medical centre, Bangalore, India
🇮🇳
Care Hospital, Hyderabad, India
🇮🇳
Columbia Asia Referral Hospital, Bengaluru, India

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

Phase 2

Terminated

Conditions: Schizophrenia

Interventions: Drug: BI 409306
Drug: Placebo

First Posted Date: 2017-11-22

Last Posted Date: 2022-05-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 264

Registration Number: NCT03351244

Locations: 🇺🇸
Collaborative Neuroscience Network, LLC (CNS), Torrance, California, United States
🇺🇸
Reliable Clinical Research, Hialeah, Florida, United States
🇺🇸
Hassman Research Institute, Berlin, New Jersey, United States

and more 54 locations

This Study Tests the Safety, Tolerability and How Different Doses of BI 1265162 Are Taken up in the Body of Healthy Men

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1265162
Drug: Placebo

First Posted Date: 2017-11-21

Last Posted Date: 2022-04-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 57

Registration Number: NCT03349723

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding

Phase 3

Completed

Conditions: Hemorrhage

Interventions: Drug: Idarucizumab

First Posted Date: 2017-11-17

Last Posted Date: 2022-06-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 19

Registration Number: NCT03343704

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, China
🇨🇳
Cardiovascular Institute and Fu Wai Hospital, Beijing, China
🇨🇳
Beijing AnZhen Hospital, Beijing, China

and more 10 locations

This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax

Phase 1

Withdrawn

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell

Interventions: Drug: Venetoclax
Drug: BI 836826

First Posted Date: 2017-11-17

Last Posted Date: 2018-01-09

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT03343678

Real World Glycemic Effectiveness of Linagliptin

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Linagliptin

First Posted Date: 2017-11-09

Last Posted Date: 2019-05-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 11001

Registration Number: NCT03338803

Locations: 🇺🇸
Optum, Eden Prairie, Minnesota, United States

A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin

Phase 3

Completed

Conditions: Heart Failure

Interventions: Drug: Empagliflozin
Drug: Placebo

First Posted Date: 2017-11-06

Last Posted Date: 2021-06-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 72

Registration Number: NCT03332212

Locations: 🇬🇧
John Radcliffe Hospital, Oxford, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy